Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: A retrospective analysis

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 2, 2010, Pages 283-292

  Stec, Rafai ^a   Bodnar, Lubomir ^a   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Age 65 years; Capecitabine; Colorectal cancer; FOLFIRI; Toxicity; Treatment eycacy

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; POLAND; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; VOMITING; ANALYSIS OF VARIANCE; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE COURSE; FEASIBILITY STUDY; PATHOLOGY; RISK; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANEMIA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; NEUTROPENIA; ODDS RATIO; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 74049153396     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0660-y     Document Type: Article

References (24)

1. Bennett RG, Greenought WBIII (1993) Approach to acute diarhoea in elderly. Gastrentrol Clin North Am 22:517-533.
2. Cassidy J, Twelves C, Van Cutsem E et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety proWle compared with intravenous 5-Xuorouracil/leucovorin. Ann Oncol 13:566-575.
3. Common Toxicity Criteria (1993) In: Investigator's handbook. A manual for participants in clinical trials of investigational agents sponsored by The Division of Cancer Treatment, National Cancer Institute, NIH 93-2770.
4. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with Xuorouracil compared with Xuorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047.
5. Dubsky P, Sevelda P, Jakesz R et al (2008) Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-Xuorouracil chemotherapy. Clin Cancer Res 14:2082-2087.
6. Feliu J, Escudero P, Llosa F et al (2005) Capecitabine as Wrst-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J Clin Oncol 23:3104-3111.
7. Folprecht G, Seymour MT, Saltz L et al (2008) Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2, 691 patients in randomized controlled trials. J Clin Oncol 26:1443-1451.
8. Grothey A, Sargent D, Goldberg RM, Schmoll H-J (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214.
9. Ho C, Ng K, O'Reilly S, Gill S (2005) Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. Clin Colorectal Cancer 5:279-282.
10. Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous Xuorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282-2292.
11. Jackson NA, Barrueco J, Soufi-Mahjoubi R et al (2009) Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer. Cancer 115:2617-2629.
12. Krzakowski M, Jassem J (2006) Zasady oceny wartomci leczenia systemowego w onkologii. In: Krakowski M (ed) Onkologia Kliniczna. Wydawnictwo Medyczne Borgis, Warszawa, pp 653-655.
13. Lagautriere F, Valvano L, Chaazl M et al (1998) Prognostic factors in colorectal adenocarcinoma. Ann Ital Chir 69:491-497.
14. Lichtman SM, Villani G (2000) Chemotherapy in the elderly: pharmacologic considerations. Cancer Control 7:548-556.
15. Nowacki M (2006) Rak jelita grubego. In: Krakowski M (ed) Onkologia Kliniczna. Wydawnictwo Medyczne Borgis, Warszawa, pp 889-907.
16. Nowacki M, Bielecki K, Drews M (2003) Nowotwory jelita grubego. In: Szawiowski AW, Szmidt J (eds) Zasady diagnostyki i chirurgicznego leczenia nowotworów w Polsce. Fundacja-Polski Przeglad Chirurgiczny, Warszawa, p 226.
17. O'Connell JB, Maggard AM, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer Sixth Edition Staging. J Natl Cancer Inst 96:1420-1425.
18. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus Xuorouracil and leucovorin for metastatic colorectal cancer. New Engl J Med 343:905-914.
19. Seymour MT, Maughan TS, Wasan HS et al (2007) Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial. J Clin Oncol 25(Suppl) (abstract 9030).
20. Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous Xuorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097-4106.
21. Van Cutsem E, Nowacki M, Lang I et al (2007) Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 25:18S (Suppl.) (abstr 4000).
22. Weissenberger C, Geissler M, Otto F et al (2006) Anemia and longterm outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002). World J Gastroenterol 12:1849-1858.
23. Wojciechowska U, Didkowska J, Tarnowski W, Katojski (2006) In: Nowotwory ziomliwe w Polsce w 2004 roku. Centrum Onkologii, Instytut im. Marii Skiodowskiej-Curie, pp 43-46.
24. Yoshino T, Boku N, Onozawa Y et al (2007) Efficacy and safety of an irinotecan plus bolus 5-Xuorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. Jpn J Clin Oncol 37:686-691.